Literature DB >> 34596081

Characterization of the Population Affected by the 6-Month Recertification Criterion of the Ryan White HIV/AIDS Program's AIDS Drug Assistance Program in Washington State, 2017-2019.

Steven Erly1,2, Christine M Khosropour1, Anjum Hajat1, Monisha Sharma3, Jen Reuer2, Martha Grimm2, Kelse Kwaiser2, Julia C Dombrowski1,4.   

Abstract

INTRODUCTION: AIDS Drug Assistance Programs (ADAPs) provide financial support for medical care for people living with HIV (PLWH) in the United States. Federal policy requires that clients recertify for the program every 6 months, which has been described as a barrier to care access. Our objective was to describe the prevalence of and factors associated with ADAP disenrollment in Washington State.
METHODS: Between 2017 and 2019, we categorized ADAP clients by the success of their recertification applications as follows: (1) continuously enrolled, (2) ruled ineligible, or (3) disenrolled if they failed to recertify. We compared individuals who were disenrolled with those who were continuously enrolled by demographic and socioeconomic characteristics and engagement with case management using data from the Washington State HIV Surveillance and Ryan White data systems.
RESULTS: From 2017 to 2019, 5480 clients were enrolled in ADAP, of whom 1423 (26%) were disenrolled and 984 (18%) were ruled ineligible at least once. Compared with those who were continuously enrolled, disenrolled PLWH were more likely to be Black [unadjusted prevalence ratio (PR) vs White 1.31, 95% confidence interval (CI): 1.17 to 1.46], uninsured (PR vs private insurance 1.24, 95% CI: 1.10 to 1.40), and younger (PR 25-34 vs 35-44 years 1.23, 95% CI: 1.08 to 1.41). The median time to return after disenrollment was 12 months (95% CI: 8 to 19 months).
CONCLUSIONS: Disenrollment after failure to recertify was the most common reason why PLWH lost ADAP coverage in Washington State. ADAP recertification procedures disproportionately affect Black, young, and uninsured PLWH and may contribute to disparities in HIV outcomes.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34596081      PMCID: PMC8665124          DOI: 10.1097/QAI.0000000000002824

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  17 in total

1.  Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications.

Authors:  Noah C Godwin; James H Willig; Christa R Nevin; Hui-Yi Lin; Jeroan Allison; Kathy Gaddis; Jennifer Peterson; Michael S Saag; Michael J Mugavero; James L Raper
Journal:  Health Serv Res       Date:  2011-01-06       Impact factor: 3.402

2.  A qualitative study of underutilization of the AIDS drug assistance program.

Authors:  Kristin M Olson; Noah C Godwin; Sara Anne Wilkins; Michael J Mugavero; Linda D Moneyham; Larry Z Slater; James L Raper
Journal:  J Assoc Nurses AIDS Care       Date:  2014-02-04       Impact factor: 1.354

3.  Rural-Urban Differences in Late-Stage Breast Cancer: Do Associations Differ by Rural-Urban Classification System?

Authors:  Sandi L Pruitt; Jan M Eberth; E Scott Morris; David B Grinsfelder; Erica L Cuate
Journal:  Tex Public Health J       Date:  2015

4.  Financial Barriers and Lapses in Treatment and Care of HIV-Infected Adults in a Southern State in the United States.

Authors:  David A Wohl; Rita K Kuwahara; Kamran Javadi; Christine Kirby; David L Rosen; Sonia Napravnik; Claire Farel
Journal:  AIDS Patient Care STDS       Date:  2017-10-17       Impact factor: 5.078

5.  Barriers and facilitators to engagement of vulnerable populations in HIV primary care in New York City.

Authors:  Robert H Remien; Laurie J Bauman; Joanne E Mantell; Benjamin Tsoi; Javier Lopez-Rios; Rosy Chhabra; Abby DiCarlo; Dana Watnick; Angelic Rivera; Nehama Teitelman; Blayne Cutler; Patricia Warne
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

6.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

7.  Health insurance and AIDS Drug Assistance Program (ADAP) increases retention in care among women living with HIV in the United States.

Authors:  Emma Sophia Kay; Andrew Edmonds; Christina Ludema; Adaora Adimora; Maria L Alcaide; Aruna Chandran; Mardge H Cohen; Mallory O Johnson; Seble Kassaye; Mirjam-Colette Kempf; Caitlin A Moran; Oluwakemi Sosanya; Tracey E Wilson
Journal:  AIDS Care       Date:  2020-11-25

8.  Barriers and facilitators to patient retention in HIV care.

Authors:  Baligh R Yehia; Leslie Stewart; Florence Momplaisir; Aaloke Mody; Carol W Holtzman; Lisa M Jacobs; Janet Hines; Karam Mounzer; Karen Glanz; Joshua P Metlay; Judy A Shea
Journal:  BMC Infect Dis       Date:  2015-06-28       Impact factor: 3.090

9.  A mathematical model to estimate the state-specific impact of the Health Resources and Services Administration's Ryan White HIV/AIDS Program.

Authors:  Pamela W Klein; Stacy M Cohen; Evin Uzun Jacobson; Zihao Li; Glenn Clark; Miranda Fanning; Rene Sterling; Steven R Young; Stephanie Sansom; Heather Hauck
Journal:  PLoS One       Date:  2020-06-22       Impact factor: 3.240

10.  Innovations in Human Immunodeficiency Virus (HIV) Care Delivery During the Coronavirus Disease 2019 (COVID-19) Pandemic: Policies to Strengthen the Ending the Epidemic Initiative-A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.

Authors:  Wendy S Armstrong; Allison L Agwu; Ernie-Paul Barrette; Rachel Bender Ignacio; Jennifer J Chang; Jonathan A Colasanti; Michelle Floris-Moore; Marwan Haddad; Lynsay MacLaren; Andrea Weddle
Journal:  Clin Infect Dis       Date:  2021-01-23       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.